Board Change

RNS Number : 2808C

Oxford Biomedica PLC

29 August 2008

 



FOR IMMEDIATE RELEASE	29 AUGUST 2008

OXFORD BIOMEDICA ANNOUNCES BOARD CHANGES

Oxford, UK - 29 August 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today changes to the composition of its Board of Directors. With effect from 28 August 2008, Dr Mike McDonald, Chief Executive Officer, has left the Board of Oxford BioMedica. 

With immediate effect, John Dawson, who was appointed as Non-Executive Director on 1 August 2008, will take the position of Acting Chief Executive Officer.  

Commenting on these developments, Professor Alan Kingsman, Oxford BioMedica's Chairman, said: 'We would like to thank Dr McDonald for his major contributions to the TroVax and ProSavin programmes. His expertise in drug development programmes and his clinical leadership have been much valued. We wish him well for the future. We welcome John Dawson to the role of Acting Chief Executive Officer, and we look forward to making a permanent appointment in due course.'

-Ends-

For further information, please contact:
Oxford BioMedica plc:  John Dawson, Acting Chief Executive Officer Andrew Wood, Chief Financial Officer	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
NM Rothschild & Sons: Lynn Drummond/ Christopher Bath	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications	Tel: [phone]
Scientific/Trade Press Enquiries: Holly Griffiths/ Katja Stout College Hill Life Sciences	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. 

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. The lead product candidate is TroVax®, an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. TroVax is in Phase III development. Oxford BioMedica has three other products in clinical development, including ProSavin®, a novel gene-based treatment for Parkinson's disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. 

Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

BOAFKCKKPBKKFFB